# Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia

> **NCT00046930** · PHASE3 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group** · enrollment: 449 (actual)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** sargramostim
- **DRUG:** cytarabine
- **DRUG:** daunorubicin hydrochloride
- **DRUG:** zosuquidar trihydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00046930
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09-17
- **Primary completion:** 2009-06
- **Final completion:** —
- **Target enrollment:** 449 (ACTUAL)
- **Last updated:** 2023-07-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00046930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00046930, "Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00046930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*